Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%
Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
When and Why to Use CAC Scoring
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
From Risk to Results: Cases in ASCVD Prevention and Treatment
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
NYHA FC and Finerenone Response: Clinical Trial Insights
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Gautam Nayak, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.